GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Monday, 13 Oct 2014 | 1:19 PM ET

    Amgen Inc. fell $1.25 or. 9 percent, to $136.14. Biogen Idec fell $3.26 or 1.0 percent, to $311.88. Celgene Corp. fell $1.31 or 1.4 percent, to $89.62.

  • Early Glance: Biotechnology companies Monday, 13 Oct 2014 | 10:29 AM ET

    Amgen Inc. fell$. 88 or. 6 percent, to $136.51. Biogen Idec fell $5.01 or 1.6 percent, to $310.13. Celgene Corp. fell $1.50 or 1.6 percent, to $89.43.

  • Business Highlights Friday, 10 Oct 2014 | 6:14 PM ET

    Olive Garden seen through an unlimited pasta pass. NEW YORK— The " Never Ending Pasta Pass" card from Olive Garden not only promised weeks of unlimited pasta, but a look into why the chain is fighting to hold onto customers. It was a successful publicity stunt for Olive Garden's parent company, Darden Restaurants.

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of...

  • Oct 10- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12- week course of treatment to rid patients of the liver-destroying viral infection. "We believe the price is very reasonable and attractive to payors as it is a significant discount to previous regimens that cost upwards...

  • U.S. FDA approves Gilead's all-oral hepatitis C drug Friday, 10 Oct 2014 | 1:58 PM ET

    Oct 10- U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection. The new drug, to be sold under the brand name Harvoni, combines Gilead's $1,000- per-pill Sovaldi, with another drug, ledipasvir, and eliminates the...

  • New once-a-day pill for hepatitis C wins FDA OK Friday, 10 Oct 2014 | 1:53 PM ET

    WASHINGTON— Federal health officials have approved a daily pill that can cure the most common form of hepatitis C without the grueling pill-and-injection cocktail long used to treat the virus. But the drug's $1,125- per-pill price is sure to increase criticism of drugmaker Gilead Sciences, whose pricing strategy for an older hepatitis drug has already drawn...

  • Midday Glance: Biotechnology companies Friday, 10 Oct 2014 | 1:19 PM ET

    Amgen Inc. rose $1.99 or 1.4 percent, to $139.57. Biogen Idec rose $2.70 or. 8 percent, to $321.89. Celgene Corp. rose$. 47 or. 5 percent, to $92.85.

  • Early Glance: Biotechnology companies Friday, 10 Oct 2014 | 10:28 AM ET

    Amgen Inc. rose $2.48 or 1.8 percent, to $140.06. Biogen Idec rose $4.17 or 1.3 percent, to $323.36. Celgene Corp. rose$. 40 or. 4 percent, to $92.78.

  • Final Glance: Biotechnology companies Thursday, 9 Oct 2014 | 6:01 PM ET

    Amgen Inc. fell $2.49 or 1.8 percent, to $137.58. Biogen Idec fell $5.40 or 1.7 percent, to $319.19. Celgene Corp. fell $2.51 or 2.6 percent, to $92.38.

  • Midday Glance: Biotechnology companies Thursday, 9 Oct 2014 | 2:06 PM ET

    Amgen Inc. fell $2.06 or 1.5 percent, to $138.01. Biogen Idec fell $6.40 or 2.0 percent, to $318.19. Celgene Corp. fell $2.29 or 2.4 percent, to $92.60.

  • Early Glance: Biotechnology companies Thursday, 9 Oct 2014 | 11:31 AM ET

    Amgen Inc. fell$. 91 or. 6 percent, to $139.16. Biogen Idec fell $3.36 or 1.0 percent, to $321.23. Celgene Corp. fell $1.08 or 1.1 percent, to $93.81.

  • NEA, known for backing companies such as Workday Inc, Salesforce.com Inc and Gilt Groupe, is one of the world's top venture firms, with its latest fund totalling $2.6 billion. Health science is one area where women venture capitalists appear to be making serious gains, with some of the most accomplished health investors, including Beth Seidenberg of Kleiner...

  • Final Glance: Biotechnology companies Wednesday, 8 Oct 2014 | 6:02 PM ET

    Amgen Inc. rose $4.04 or 3.0 percent, to $140.07. Biogen Idec rose $8.67 or 2.7 percent, to $324.59. Celgene Corp. rose $2.44 or 2.6 percent, to $94.89.

  • Midday Glance: Biotechnology companies Wednesday, 8 Oct 2014 | 1:33 PM ET

    Amgen Inc. rose $1.67 or 1.2 percent, to $137.70. Biogen Idec rose $1.09 or. 3 percent, to $317.01. Celgene Corp. rose$. 29 or. 3 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 8 Oct 2014 | 10:52 AM ET

    Amgen Inc. rose$. 59 or. 4 percent, to $136.62. Biogen Idec fell $2.67 or. 8 percent, to $313.25. Celgene Corp. fell$. 22 or. 2 percent, to $92.23.

  • Final Glance: Biotechnology companies Tuesday, 7 Oct 2014 | 6:59 PM ET

    Amgen Inc. fell $1.58 or 1.1 percent, to $136.03. Biogen Idec fell $9.15 or 2.8 percent, to $315.92. Celgene Corp. fell $2.06 or 2.2 percent, to $92.45.

  • Midday Glance: Biotechnology companies Tuesday, 7 Oct 2014 | 1:16 PM ET

    Amgen Inc. fell$. 85 or. 6 percent, to $136.76. Biogen Idec fell $6.25 or 1.9 percent, to $318.83. Celgene Corp. fell $1.63 or 1.7 percent, to $92.87.

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...

  • Early Glance: Biotechnology companies Tuesday, 7 Oct 2014 | 10:28 AM ET

    Amgen Inc. fell$. 50 or. 4 percent, to $137.11. Biogen Idec fell $6.05 or 1.9 percent, to $319.03. Celgene Corp. fell$. 96 or 1.0 percent, to $93.54.